- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
- XOMA Royalty to Present at Investor Conferences in March
- XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
- XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
- Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
- XOMA Royalty Declares Quarterly Preferred Stock Dividends
- XOMA Royalty to Present at Upcoming Investor Conferences in September
- XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
